Institut Curie has supplied an undisclosed sum to its second immuno-oncology spinout, Honing Biosciences, which will focus on improved drug delivery mechanisms.
France-based immuno-oncology developer Honing Biosciences has officially spun out of research centre Institut Curie, which equipped the startup with an undisclosed amount of seed capital.
Honing Biosciences will advance a protein delivery mechanism mainly focused on reprogramming immune system cells from the chimeric antigen receptor (Car-T cells), so they can recognise and destroy cancerous bodies.
The spinout aims to overcome some of the problems that have stalled other Car-T approaches, such as toxicity when treating blood cancers and…
